Increased collaboration

The best brains can be found across different sectors and increased collaboration between industry, academia, the NHS and regulators must be fostered in order to achieve a reduction in the time it takes to develop new medicines for patients.

This could take place in pre-competitive or non-competitive research, for example in areas such as predictive toxicology, drug target identification and validation and the identification of novel biomarkers. Some good examples are:

The Stem Cells for Safer Medicines public-private partnership, which specialises in the identification of stem cell derived cell lines for predictive toxicology – www.sc4sm.org
The Innovative Medicines Initiative – www.imi.europa.eu
The MRC-ABPI immunology and inflammation initiative – www.mrc.ac.uk
The Therapeutic Capability Clusters as proposed in the Office of Life Sciences 2009 Life Sciences Blueprint

Print this page

Get in touch

Please choose the subject of your enquiry from the list below:

Enter the above code here:

Can't read? Try different words.

Submit

I am happy for ABPI to keep my details on file and to send me details of future ABPI work and services. ABPI will not sell your data to any third party or send you any information about products or services that ABPI has no direct connection with.

The Association of the British Pharmaceutical Industry

7th floor, Southside, 105 Victoria Street,
London, SW1E 6QT
Telephone +44 (0) 870 890 4333
ABPI Cymru Wales
ABPI Northern Ireland
ABPI Scotland

The Prescription Medicines Code of Practice Authority (PMCPA) is responsible for administering the ABPI Code of Practice for the Pharmaceutical Industry at arm's length of the ABPI itself.

The Office of Health Economics (OHE) provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.